PRINCETON, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that it plans to present at NASDAQ’s 16th Investor Program at 10:00 AM Eastern Time on December 8, 2005. The conference is being held at The Renaissance Chancery Court Hotel in London, England. Medarex’s presentation will be webcast live and will be available for replay through the Webcasts page in the Investor Relations section of the Medarex website via the Internet at www.medarex.com/Investor/Webcasts.htm.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Twenty-six of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with two of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221,both of Medarex, Inc.
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
